NCT07052006View on ClinicalTrials.gov

HT-6184 in Subjects With MDS

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 9, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions
Myelodysplastic SyndromeAnemia in Myelodysplastic Syndromes
Interventions
DRUG

HT-6184

Oral HT-6184

Trial Locations (10)

249203

All India Institute of Medical Sciences, Dehradun

380009

Hemato Oncology Clinica Ahmedabad Pvt. Ltd. Vedanta Institute of Medical Sciences, Ahmedabad

380015

Shalby Hospital, Ahmedabad

416005

Dr. Bafna's Star Superspeciality Clinic and Hospital, Kolhāpur

500033

Apollo Cancer Centre, Hyderabad

530040

HCG Cancer Center Vizag, Visakhapatnam

625107

Meenakshi Mission Hospital and Research Centre, Madurai

670103

Malabar Cancer Center, Kannur

700014

Nil Ratan Sircar Medical College and Hospital, Kolkata

700160

Tata Medical Center, Kolkata

Sponsors
All Listed Sponsors
lead

Halia Therapeutics, Inc.

INDUSTRY